We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Pharmacist Intervention for Glycemic Control in The Community (RxING)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01335763
Recruitment Status : Completed
First Posted : April 14, 2011
Last Update Posted : November 6, 2013
Information provided by (Responsible Party):
Ross T. Tsuyuki, University of Alberta

Brief Summary:

Background: Approximately 1.9 million Canadians are living with diabetes and this is estimated to increase by 75% over the next few decades. Pharmacists are front line primary healthcare professionals who see patients with diabetes frequently and in Alberta, they have been allowed to prescribe medications and order laboratory tests. As such, pharmacists could systematically identify poorly controlled diabetes patients and provide greater access to diabetes interventions to improve blood sugar control.

Objective: The aim of this study is to determine the effect of a community pharmacist intervention on blood sugar control in individuals with poorly controlled diabetes.

Project description:

100 adults with type 2 diabetes and uncontrolled blood sugar will be defined by the participating pharmacists. Blood sugar control is going to assessed using hemoglobin A1c test (a blood test to measure individual's blood sugar control over the last 3 months). This test requires obtaining a blood spot from the patient which will be obtained by pricking his/her fingertip. Based on the hemoglobin A1c test result the pharmacist will assess the patient's need for insulin glargine, if the patient needs insulin glargine the pharmacist is going to prescribe it for him/her and educate him/her on its use. Patients are going to be followed up closely by the pharmacists for 6 months with regular updates to the patients' family physicians. This multi-centre study should demonstrate pharmacists' ability to improve glycemic control and improve access to care.

Condition or disease Intervention/treatment
Type 2 Diabetes Drug: Insulin glargine

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 100 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pharmacist Intervention for Glycemic Control in The Community (The RxING Study)
Study Start Date : April 2011
Primary Completion Date : October 2012
Study Completion Date : October 2012

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Insulin glargine
10 units at bedtime of insulin glargine will be prescribed to the patients who has HbA1c levels of 7.5-11%. Insulin glargine dose is going to be titrated by increments of 1 unit daily by the patient to achieve a morning fasting glucose of <=5.5mmol/L
Drug: Insulin glargine
10 units at bedtime of insulin glargine will be prescribed to the patients who has HbA1c levels of 7.5-11%. Insulin glargine dose is going to be titrated by increments of 1 unit daily by the patient to achieve a morning fasting glucose of <=5.5mmol/L
Other Name: Lantus

Primary Outcome Measures :
  1. The change in HbA1c from baseline to week 26 [ Time Frame: 6 months ]
    The change of the patients' HbA1c between the baseline and the 26 week visits

Secondary Outcome Measures :
  1. Quality of life and patient satisfaction. [ Time Frame: 6 months ]
    Quality of life and patient satisfaction is going to be measured through using the questionnaires Audit of Diabetes-Dependent Quality of Life (ADDQoL), Diabetes Treatment Satisfaction Questionnaire and Diabetes Treatment Satisfaction Questionnaire change (DTSQ and DTSQc)

  2. Proportion of patients achieving the target HbA1c [ Time Frame: 6 months ]
    Proportion of patients achieving HbA1c of ≤7.0% during follow-up

  3. Type and degree of dosage changes in oral hypoglycemic agents [ Time Frame: 6 months ]
    The type and the degree of changes in the oral hypoglycemic dosing regimen

  4. Persistence on insulin glargine [ Time Frame: 6 months ]
    Percentage of patients still taking insulin at the end of follow-up

  5. Safety [ Time Frame: 6 months ]
    Number of hypoglycemic episodes; symptomatic confirmed and severe (i.e., Requiring the help from a third party), as defined by the CDA guidelines

  6. Health economic evaluation [ Time Frame: 6 months ]
    Cost-effectiveness analyses from a healthcare payor (government) perspective. Costs will include pharmacist training, time spent with patients, pharmaceutical care processes (includes number of face-to-face meetings, time spent with the patient, number and duration of phone calls, number and type of testing per patient, equipment and testing costs, medication costs and out of pocket costs for patients). Clinical benefits will be estimated by modeling the A1C reduction with clinical trials estimates of event reductions

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or Female over 18 years of age
  • Type 2 diabetes for at least 6 months
  • Taking 1 or more oral hypoglycemic agents
  • Patient attending your community pharmacy where you decided that addition of insulin glargine may be of benefit to the patient
  • Baseline HbA1c 7.5 - 11%
  • Signed informed consent

Exclusion Criteria:

  • Have used, or currently using, Insulin
  • History of ketoacidosis
  • Pregnant
  • Works night shift
  • Renal impairment(Serum Creatinine: females ≥ 124 mmol/l, males ≥ 133 mmol/l)
  • Clinically unstable
  • Unwilling/unable to attend follow up visits
  • Unlikely to adhere to study procedures (eg. due to cognitive limitations, severe psychiatric disorder or alcoholism)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01335763

Canada, Alberta
Edmonton, Alberta, Canada, T6G 2C8
Sponsors and Collaborators
University of Alberta

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Ross T. Tsuyuki, Professor of Medicine (Cardiology) and Director, EPICORE Centre University of Alberta, University of Alberta
ClinicalTrials.gov Identifier: NCT01335763     History of Changes
Other Study ID Numbers: LANTU_L_05128*
First Posted: April 14, 2011    Key Record Dates
Last Update Posted: November 6, 2013
Last Verified: August 2012

Keywords provided by Ross T. Tsuyuki, University of Alberta:
Multicentre before-after design
Glycemic control
Community pharmacists

Additional relevant MeSH terms:
Insulin, Globin Zinc
Insulin Glargine
Hypoglycemic Agents
Physiological Effects of Drugs